Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View Item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Thumbnail
View/Open
Supporting information (63.31Kb)
Publication Date
2017-10-20
ICR Author
Marsden,
Author
Martínez, C
Gayoso, J
Canals, C
Finel, H
Peggs, K
Dominietto, A
Castagna, L
Afanasyev, B
Robinson, S
Blaise, D
Corradini, P
Itälä-Remes, M
Bermúdez, A
Forcade, E
Russo, D
Potter, M
McQuaker, G
Yakoub-Agha, I
Scheid, C
Bloor, A
Montoto, S
Dreger, P
Sureda, A
Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Type
Journal Article
Metadata
Show full item record
Abstract
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO ( P = .26) and higher in MUD ( P = .003), and risk of relapse was lower in both HAPLO ( P = .047) and MUD ( P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.
URL
https://repository.icr.ac.uk/handle/internal/1554
Collections
  • Other ICR Research
Version of record
10.1200/JCO.2017.72.6869
Subject
Adolescent
Adult
Aged
Bone Marrow Transplantation
Cyclophosphamide
Disease-Free Survival
Europe
Female
Graft vs Host Disease
Haplotypes
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Humans
Immunosuppressive Agents
Male
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Proportional Hazards Models
Registries
Retrospective Studies
Siblings
Transplantation, Homologous
Unrelated Donors
Young Adult
Language
eng
License start date
2017-10-20
Citation
J Clin Oncol, 2017, 35 (30), pp. 3425 - 3432

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma 

    Morgan, G (2014-02)
    Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents ...
  • Thumbnail

    How I treat prolymphocytic leukemia 

    Dearden, Claire (2012-07)
    T- and B-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. Recent studies have highlighted the ...
  • Thumbnail

    CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 

    Locke, FL; Pidala, J; Storer, B; Martin, PJ; Pulsipher, MA; Chauncey, TR; Jacobsen, N; Kröger, N; Walker, I; Light, S; Shaw, BE; Beato, F; Laport, GG; Nademanee, A; Keating, A; Socie, G; Anasetti, C (2017-03)
    Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow ...

Browse

All of ICR repositoryICR Divisions & RM Clinical UnitsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.